Literature DB >> 23787466

Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.

Maike Sauer, Katrin S Reiners, Hinrich P Hansen, Andreas Engert, Stephan Gasser, Elke Pogge von Strandmann.   

Abstract

Evasion of apoptosis is a hallmark of cancer cells. Inhibitor of apoptosis proteins (IAPs) act as endogenous inhibitors of programmed cell death and are overexpressed in several tumors including Hodgkin lymphoma (HL). Preclinical studies indicate antitumor activity of IAP antagonists and clinical studies in hematological malignancies are underway. Here, we investigate the impact of the small molecule IAP antagonist LCL161 on HL cell lines. Although the antagonist caused rapid degradation of cIAP1 leading to TNFα secretion, LCL161 did not promote apoptosis significantly. However, LCL161 induced expression of MICA and MICB, ligands for the activating immune receptor NKG2D, and enhanced the susceptibility of HL cells to NKG2D-dependent lysis by NK cells. MICA/B upregulation was dependent on activation of the DNA damage response upon LCL161 treatment. Taken together, we demonstrate a novel link between IAP inhibition, DNA damage and immune recognition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23787466     DOI: 10.1515/hsz-2013-0161

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

Review 1.  Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.

Authors:  Amber B Jones; Abbey Rocco; Lawrence S Lamb; Gregory K Friedman; Anita B Hjelmeland
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

2.  RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.

Authors:  Adeline R Lam; Nina Le Bert; David H Raulet; Stephan Gasser; Samantha Sw Ho; Yu J Shen; Li Fm Tang; Gordon M Xiong; John L Croxford; Christine X Koo; Ken J Ishii; Shizuo Akira
Journal:  Cancer Res       Date:  2014-03-03       Impact factor: 12.701

3.  Combination immune therapies to enhance anti-tumor responses by NK cells.

Authors:  Ashley Mentlik James; Adam D Cohen; Kerry S Campbell
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

4.  Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.

Authors:  V Ramakrishnan; U Painuly; T Kimlinger; J Haug; S V Rajkumar; S Kumar
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

5.  The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells.

Authors:  Kyra Fischer; Sara Tognarelli; Stefanie Roesler; Cathinka Boedicker; Ralf Schubert; Alexander Steinle; Thomas Klingebiel; Peter Bader; Simone Fulda; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

6.  CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.

Authors:  M Sauer; M Schuldner; N Hoffmann; A Cetintas; K S Reiners; O Shatnyeva; M Hallek; H P Hansen; S Gasser; E P von Strandmann
Journal:  Oncogene       Date:  2016-08-01       Impact factor: 9.867

Review 7.  The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy.

Authors:  Jessica Michie; Conor J Kearney; Edwin D Hawkins; John Silke; Jane Oliaro
Journal:  Cells       Date:  2020-01-14       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.